title: Treatment of lower respiratory tract infections with sultamicillin.
abstract: Oral tablets containing 375 mg sultamicillin were used to treat 30 adult patients of either sex suffering from lower respiratory tract infections. The dose used was one tablet every 12 h for 22 cases and one tablet every 8 h for eight cases. The duration of therapy varied between 5 and 14 days (mean 8.6 days). The therapeutic response was rated as cure in 23 (76.6%) patients, with complete disappearance of pretreatment signs and symptoms, and as improvement in seven (23.3%) patients, with amelioration of the pretreatment manifestations. All 52 microorganisms isolated before treatment were eradicated. No adverse effects were reported in 25 (83.3%) patients, whereas the remaining five (16.7%) patients reported mild loose stools with normal bowel motion. There were no abnormal changes in blood count and liver and renal functions following sultamicillin treatment.
authors.affiliation: Department of Chest Diseases, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
authors.forename: M A
authors.initials: MA
authors.lastname: Tageldin
authors.forename: A
authors.initials: A
authors.lastname: Said
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D000667:Ampicillin / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy; D002908:Chronic Disease; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D011014:Pneumonia / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013407:Sulbactam / Q000627:therapeutic use*; D013607:Tablets
chemical_list: D013607:Tablets; C035444:sultamicillin; D000667:Ampicillin; D013407:Sulbactam